Content Currently Unavailable
The Scalability Challenge in MSC Therapies
John Yoshi Shyu on why mesenchymal stem cell programs stall – and how early manufacturing decisions can determine clinical and commercial success
Content Currently Unavailable
False
John Yoshi Shyu on why mesenchymal stem cell programs stall – and how early manufacturing decisions can determine clinical and commercial success
False
False
November 7, 2014
0 min read
Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.
April 2, 2025
5 min read
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
April 1, 2025
3 min read
Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”
April 1, 2025
9 min read
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.
False
Affiliations:
Specialties:
Areas of Expertise: